National Hockey League executive diagnosed with Hodgkin's lymphoma
Former National Hockey League player and coach Mike Murphy, currently the NHL's vice-president of operations, revealed recently to Canadian media that in October he was diagnosed with Hodgkin's lymphoma.
The 59 year-old NHL executive also revealed that he was undergoing chemotherapy treatment and that radiation treatment would follow.
"If I'm blessed, I will be cancer-free come playoff time," said Murphy.
Playoff time in the NHL begins in late April.
Hockey and lymphoma
In 1997 NHL star John Cullen was diagnosed with non-Hodgkin's lymphoma and successfully underwent treatment before returning to the league, and in 2001 NHL star Saku Koivu achieved the same thing.
However few modern sports stories match that of NHL superstar Mario Lemieux, who was the game's most dominating player in 1993 when he announced he had been diagnosed with Hodgkin's lymphoma. After two months of treatment, Lemieux made a triumphant return to the ice--having received his final dose of radiation earlier in the day--to score two points in his first game back. Remarkably he would end the season as the league's top scorer, despite only playing 60 games out of 82.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
